Amanda Maxwell
European Regulatory Affairs Editor
European Regulatory Affairs Editor
UK
+36 year(s) experience
Amanda closely monitors the implementation of the Medical Device and IVD Regulations and the challenges that the sector is encountering is being in compliance in time. In so doing, she keeps in constant communication with a broad base of expert contacts around Europe. Moreover, as the UK heads for Brexit, she monitors the likely impact of political developments on the medtech sector.
Amanda also has experience in providing medtech regulatory strategy consultancy services, and is a frequently invited speaker and chair at EU meetings on medtech regulations and drug/device combination regulatory issues.
Citeline
The 9th Annual SCOPE (Summit for Clinical Trials Operations Executives) Summit has concluded: join industry expert and clinical trial planning thought leader Loni Branon as she hosts a follow-up to this important annual event, where Informa Pharma Intelligence hosted a launch party for our exciting new Citeline platform.
Topic clinical-trials
Sitetrove: 治験責任医師と治験施設情報のデータベース
Clinical Trial and Site Selection Optimization for Seasonal Respiratory Vaccines
Topic clinical-trials
Trialtrove: 医療用医薬品の臨床試験情報データベース
Alzheimer’s Disease (AD) is the most common form of dementia, and accounts for 60% to 80% of dementia cases. In this progressive disease, dementia symptoms gradually worsen over a number of years. Memory loss is mild during early stages, but individuals with late-stage Alzheimer's lose the ability to carry on a conversation and respond to their environment. The greatest known risk factor is increasing age, and the majority of people with Alzheimer's are 65 and older.
Topic alzheimers
The current state of amyloid targeting treatments in Alzheimer’s Disease was reviewed in another Citeline blog.